TLDR
- DTSS gains as Datasea advances FDA steps for acoustic BCI product
- Datasea files DUNS application for planned FDA registration process
- Acoustic BCI device targets brain health, sleep, and rehabilitation uses
- Company says FDA listing work supports its global medical tech strategy
- DTSS stock rises as acoustic health roadmap gains fresh market attention
Datasea Intelligent Technology Ltd. (DTSS) stock rose 3.02% to $1.0301 as the company advanced its FDA preparation process. The move followed a fresh update on its acoustic brain-computer interface product. The company said the work supports its broader acoustic medical strategy.
Datasea Advances FDA Registration Preparation
Datasea said it has started compliance work tied to FDA establishment registration and device listing. The process covers one acoustic brain-computer interface product in its medical technology pipeline. It also includes steps needed before future regulatory submissions.
The company submitted its Dun & Bradstreet DUNS application as part of the process. That application supports administrative requirements linked to future FDA registration activity. However, it does not represent FDA approval or clearance.
Datasea also plans to prepare establishment registration documents and device listing materials. In addition, it expects product testing and regulatory communication to follow. These steps form part of its planned United States market strategy.
Acoustic BCI Product Targets Non-Invasive Health Uses
The product uses Datasea’s acoustic medical and BCI technology roadmap. It combines acoustic stimulation, bone-conduction neuromodulation, EEG signal collection, and AI-assisted health management. Therefore, the product targets non-invasive acoustic neuromodulation scenarios.
Datasea said the product could support brain health management and rehabilitation support. It may also apply to cognitive monitoring, sleep quality, and emotional regulation. These areas sit within broader neurological health applications.
The company presents the technology as a different path from invasive BCI systems. It combines acoustic intervention with physiological monitoring and AI-based analysis. As a result, Datasea sees potential in accessibility, compliance, and commercial scale.
Company Builds Acoustic Medical Strategy
Datasea has focused on acoustic high-tech innovation and AI-powered multimodal digital solutions. Its acoustic business covers ultrasonic, infrasound, and directional sound technologies. The company applies these tools across health, wellness, hygiene, and smart scenarios.
Chief Executive Officer Zhixin Liu said the FDA preparation marks early progress. She also linked the work to Datasea’s international expansion and acoustic medical strategy. Her comments positioned the BCI product as part of a longer growth plan.
The company has not received FDA clearance or approval for U.S. commercial distribution. It also said FDA-related procedures may face timing and review uncertainties. Still, the update gave DTSS stock fresh momentum as the medical technology plan advanced.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
